Patients with refractory Crohn’s disease who previously received ustekinumab experienced clinical and endoscopic improvements ...

The FDA approved KOMZIFTI, a once-daily oral therapy for relapsed or refractory NPM1-mutated AML. ・Kura and Kyowa Kirin said the treatment will be available immediately under their joint ...

The treatment of relapsed/refractory multiple myeloma dramatically changed in recent years with the emergence of therapies ...

Ziftomenib (Komzifti; Kura Oncology and Kyowa Kirin), an oral, once-daily, selective menin inhibitor, has received approval from the FDA for the treatment of adult patients with relapsed or refractory ...

The treatment landscape for systemic lupus erythematosus (SLE) has shifted greatly in recent years, driven by the emergence ...

In the phase 2 expansion cohorts, patients with melanoma will receive imneskibart plus aldesleukin (RP2D), with the addition ...

Patients with refractory chronic cough who received twice-daily Haduvio for 21 days had decreases in cough frequency and ...

We read with interest the FUTURE study by Mohamed Abdel-Fattah and colleagues, which reported on the role and cost-effectiveness of urodynamic testing in women with refractory overactive bladder ...

As biologic options have expanded for the treatment of chronic spontaneous urticaria (CSU), the question of which one works ...

Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company ...